JP2019524851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524851A5 JP2019524851A5 JP2019510457A JP2019510457A JP2019524851A5 JP 2019524851 A5 JP2019524851 A5 JP 2019524851A5 JP 2019510457 A JP2019510457 A JP 2019510457A JP 2019510457 A JP2019510457 A JP 2019510457A JP 2019524851 A5 JP2019524851 A5 JP 2019524851A5
- Authority
- JP
- Japan
- Prior art keywords
- adenocarcinoma
- cancer
- combination
- agent
- sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000009956 adenocarcinoma Diseases 0.000 claims 35
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 12
- 101150098329 Tyro3 gene Proteins 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 8
- 201000009030 Carcinoma Diseases 0.000 claims 7
- 206010039491 Sarcoma Diseases 0.000 claims 7
- -1 bostinib Chemical compound 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 206010016629 fibroma Diseases 0.000 claims 4
- 210000000214 mouth Anatomy 0.000 claims 4
- 206010024612 Lipoma Diseases 0.000 claims 3
- 201000004458 Myoma Diseases 0.000 claims 3
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 229950008692 foretinib Drugs 0.000 claims 3
- 201000011066 hemangioma Diseases 0.000 claims 3
- 230000036244 malformation Effects 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 229950009580 merestinib Drugs 0.000 claims 3
- QHADVLVFMKEIIP-UHFFFAOYSA-N n-[3-fluoro-4-[1-methyl-6-(1h-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide Chemical compound O=C1N(C=2C=CC(F)=CC=2)C(C)=CC=C1C(=O)NC(C=C1F)=CC=C1OC1=CC=2C=NN(C)C=2C=C1C=1C=NNC=1 QHADVLVFMKEIIP-UHFFFAOYSA-N 0.000 claims 3
- 206010018404 Glucagonoma Diseases 0.000 claims 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 2
- 229960001292 cabozantinib Drugs 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229960005061 crizotinib Drugs 0.000 claims 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 206010022498 insulinoma Diseases 0.000 claims 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 2
- 210000004379 membrane Anatomy 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011571 secondary malignant neoplasm Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 claims 1
- ODIUNTQOXRXOIV-UHFFFAOYSA-N 1-[6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound C1=CC(F)=CC=C1C1=NN2C(SC=3C=C4SC(NC(=O)NCCN5CCOCC5)=NC4=CC=3)=NN=C2C=C1 ODIUNTQOXRXOIV-UHFFFAOYSA-N 0.000 claims 1
- MJSHVHLADKXCML-UHFFFAOYSA-N 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(CN3CCN(C)CC3)=CC=2)=CN1C1CCC(O)CC1 MJSHVHLADKXCML-UHFFFAOYSA-N 0.000 claims 1
- ORRNXRYWGDUDOG-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-phenylacetyl)carbamothioylamino]phenoxy]-7-methoxy-n-methylquinoline-6-carboxamide Chemical compound C1=CN=C2C=C(OC)C(C(=O)NC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=S)NC(=O)CC1=CC=CC=C1 ORRNXRYWGDUDOG-UHFFFAOYSA-N 0.000 claims 1
- KAAPXWSYROPAEL-UHFFFAOYSA-N 4-[6-(butylamino)-3-(4-morpholin-4-ylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexan-1-ol Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)=NN1C1CCC(O)CC1 KAAPXWSYROPAEL-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- CTNPALGJUAXMMC-PMFHANACSA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-n-[(2s)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound C([C@@H](O)CNC(=O)C=1C(C)=C(\C=C/2C3=CC(F)=CC=C3NC\2=O)NC=1C)N1CCOCC1 CTNPALGJUAXMMC-PMFHANACSA-N 0.000 claims 1
- GUBJNPWVIUFSTR-UHFFFAOYSA-N 5-cyano-n-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1h-imidazole-2-carboxamide Chemical compound C1CN(C(=O)CN(C)C)CCC1C(C=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1 GUBJNPWVIUFSTR-UHFFFAOYSA-N 0.000 claims 1
- DWHXUGDWKAIASB-CQSZACIVSA-N 6-[(1r)-1-[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one Chemical compound C=1N2C([C@@H](C)N3C=CC4=NC=C(C=C4C3=O)OCCOC)=NN=C2C(F)=CC=1C=1C=NN(C)C=1 DWHXUGDWKAIASB-CQSZACIVSA-N 0.000 claims 1
- KOAWAWHSMVKCON-UHFFFAOYSA-N 6-[difluoro-(6-pyridin-4-yl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1C(F)(F)C(N1N=2)=NN=C1C=CC=2C1=CC=NC=C1 KOAWAWHSMVKCON-UHFFFAOYSA-N 0.000 claims 1
- JGEBLDKNWBUGRZ-HXUWFJFHSA-N 9-[[[(2r)-1,4-dioxan-2-yl]methyl-methylsulfamoyl]amino]-2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridine Chemical compound C=1C=C2C=CC3=NC=C(C4=CN(C)N=C4)C=C3C(=O)C2=CC=1NS(=O)(=O)N(C)C[C@@H]1COCCO1 JGEBLDKNWBUGRZ-HXUWFJFHSA-N 0.000 claims 1
- HEAIZQNMNCHNFD-UHFFFAOYSA-N AMG-208 Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OCC(N1N=2)=NN=C1C=CC=2C1=CC=CC=C1 HEAIZQNMNCHNFD-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 101500021165 Aplysia californica Myomodulin-A Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008263 Cervical dysplasia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 241000483002 Euproctis similis Species 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims 1
- 241000446313 Lamella Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- VNBRGSXVFBYQNN-UHFFFAOYSA-N N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-3-pyridinecarboxamide Chemical compound O=C1C(C(=O)NC=2C=C(F)C(OC=3C(=C(N)N=CC=3)Cl)=CC=2)=C(OCC)C=CN1C1=CC=C(F)C=C1 VNBRGSXVFBYQNN-UHFFFAOYSA-N 0.000 claims 1
- UFICVEHDQUKCEA-UHFFFAOYSA-N N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide Chemical compound CN1C=NC(C=2SC3=C(OC=4C(=CC(NC(=S)NC(=O)CC=5C=CC=CC=5)=CC=4)F)C=CN=C3C=2)=C1 UFICVEHDQUKCEA-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108010053911 PRS-110 Proteins 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229950009568 bemcentinib Drugs 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 201000005217 chondroblastoma Diseases 0.000 claims 1
- 210000004252 chorionic villi Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 210000003372 endocrine gland Anatomy 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001752 female genitalia Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 210000004195 gingiva Anatomy 0.000 claims 1
- 229950007540 glesatinib Drugs 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000009499 grossing Methods 0.000 claims 1
- SIXVRXARNAVBTC-UHFFFAOYSA-N gsk2606414 Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 SIXVRXARNAVBTC-UHFFFAOYSA-N 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000002655 heart sarcoma Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 210000000260 male genitalia Anatomy 0.000 claims 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- VQYYQSZNRVQLIS-UHFFFAOYSA-N n-[3-fluoro-4-[7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl]oxyphenyl]-1,5-dimethyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound CN1C(C)=C(C(=O)NC=2C=C(F)C(OC=3C4=CC=C(OCC(C)(C)O)C=C4N=CC=3)=CC=2)C(=O)N1C1=CC=CC=C1 VQYYQSZNRVQLIS-UHFFFAOYSA-N 0.000 claims 1
- PDYXPCKITKHFOZ-UHFFFAOYSA-N n-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1h-pyridine-3-carboxamide Chemical compound NC1=NC=CC(OC=2C(=CC(NC(=O)C=3C(C(C=4C=CC(F)=CC=4)=CNC=3)=O)=CC=2)F)=C1Cl PDYXPCKITKHFOZ-UHFFFAOYSA-N 0.000 claims 1
- FKCWHHYUMFGOPY-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=CN(C(C)C)C(=O)N1C1=CC=C(F)C=C1 FKCWHHYUMFGOPY-UHFFFAOYSA-N 0.000 claims 1
- ISPBCAXOSOLFME-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)pyrazole-3-carboxamide Chemical compound N1=C(C(=O)NC=2C=C(F)C(OC=3C4=CC(OC)=C(OC)C=C4N=CC=3)=CC=2)C(OCC)=CN1C1=CC=C(F)C=C1C ISPBCAXOSOLFME-UHFFFAOYSA-N 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 229950008835 neratinib Drugs 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 210000003254 palate Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000009996 pancreatic endocrine effect Effects 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 208000004259 scirrhous adenocarcinoma Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000001839 skull cancer Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 208000010485 smooth muscle tumor Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229950009455 tepotinib Drugs 0.000 claims 1
- AHYMHWXQRWRBKT-UHFFFAOYSA-N tepotinib Chemical compound C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229950005976 tivantinib Drugs 0.000 claims 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 claims 1
- 208000013706 tumor of meninges Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379169P | 2016-08-24 | 2016-08-24 | |
| US62/379,169 | 2016-08-24 | ||
| US201762521176P | 2017-06-16 | 2017-06-16 | |
| US62/521,176 | 2017-06-16 | ||
| PCT/US2017/048075 WO2018039275A1 (en) | 2016-08-24 | 2017-08-22 | Combinations for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524851A JP2019524851A (ja) | 2019-09-05 |
| JP2019524851A5 true JP2019524851A5 (https=) | 2020-09-24 |
Family
ID=61246270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510457A Pending JP2019524851A (ja) | 2016-08-24 | 2017-08-22 | がんを治療するための組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190224200A1 (https=) |
| EP (1) | EP3503887A4 (https=) |
| JP (1) | JP2019524851A (https=) |
| CN (1) | CN109715157A (https=) |
| WO (1) | WO2018039275A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1608378A1 (en) | 2003-04-02 | 2005-12-28 | Nexmed (Holdings), Inc. | Prostaglandin compositions and their use for the treatment of vasospasm |
| US11247990B1 (en) | 2017-12-07 | 2022-02-15 | Array Biopharma Inc | Bicyclic fused pyridine compounds as inhibitors of TAM kinases |
| US11946094B2 (en) * | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| WO2020124043A1 (en) * | 2018-12-13 | 2020-06-18 | Gordon Erlinda M | Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy |
| US20220089540A1 (en) * | 2019-01-17 | 2022-03-24 | Board Of Trustees Of Michigan State University | Compositions and methods for immune modulation and treatment of cancer |
| US12611403B2 (en) | 2020-06-02 | 2026-04-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Combined pharmaceutical composition of c-Met kinase inhibitor and anti-PD-L1 antibody |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201402004YA (en) * | 2011-11-14 | 2014-05-29 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| EP3027623A4 (en) | 2013-08-02 | 2017-03-01 | Ignyta, Inc. | METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS |
| JP2017507900A (ja) * | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| US9555031B2 (en) * | 2014-04-11 | 2017-01-31 | The University Of North Carolina At Chapel Hill | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity |
| CN105085680A (zh) * | 2014-05-23 | 2015-11-25 | 复旦大学 | 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用 |
| TW201618775A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物 |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| US10876176B2 (en) * | 2014-12-18 | 2020-12-29 | Aravive Biologics, Inc. | Antifibrotic activity of GAS6 inhibitor |
-
2017
- 2017-08-22 WO PCT/US2017/048075 patent/WO2018039275A1/en not_active Ceased
- 2017-08-22 EP EP17844308.1A patent/EP3503887A4/en not_active Withdrawn
- 2017-08-22 US US16/327,301 patent/US20190224200A1/en not_active Abandoned
- 2017-08-22 JP JP2019510457A patent/JP2019524851A/ja active Pending
- 2017-08-22 CN CN201780056350.1A patent/CN109715157A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524851A5 (https=) | ||
| JP2019527231A5 (https=) | ||
| CN103547315A (zh) | 用于治疗腺样囊性癌的4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮 | |
| CN106794336B (zh) | 病毒预防性治疗方法和暴露前预防性试剂盒 | |
| JP2014526462A5 (https=) | ||
| RU2012151571A (ru) | Лекарственные препараты для лечения рака | |
| BR112019014127A2 (pt) | Composição farmacêutica para tratamento de tumores | |
| JP2019502741A5 (https=) | ||
| BR112020001821A2 (pt) | combinação terapêutica de um inibidor de tirosina quinase de egfr de terceira geração e um inibidor de quinase dependente de ciclina | |
| CN107296811A (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| EP3638232A1 (en) | Tinostamustine for use in treating sarcoma | |
| CN114652723A (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
| JP2015517523A5 (https=) | ||
| CN115006397A (zh) | 一种预防或治疗肿瘤疾病的药物用途 | |
| CN101107001A (zh) | 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂 | |
| JP2019516728A (ja) | 抗がん組合せ治療 | |
| TW202042810A (zh) | 一種含cdk4/6抑制劑的組合物與阿那曲唑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| TW202519218A (zh) | 蛋白質酪胺酸磷酸酶抑制劑之組合 | |
| WO2020228656A1 (zh) | 用于联合治疗软组织肉瘤的喹啉衍生物 | |
| PT1757283E (pt) | Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro | |
| KR102744499B1 (ko) | 비인두암을 치료하기 위한 퀴놀린 유도체 | |
| CN115607678A (zh) | 用于治疗癌症的组合疗法 | |
| Yukutake et al. | Favorable management of repeated serous retinal detachment with continued tumor response in a patient with intrahepatic cholangiocarcinoma during treatment with pemigatinib | |
| CN108904510A (zh) | 地塞米松用于抑制或治疗胰腺癌的用途 |